Verition Fund Management LLC Bio Xcel Therapeutics, Inc. Transaction History
Verition Fund Management LLC
- $16.5 Billion
- Q2 2024
A detailed history of Verition Fund Management LLC transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 25,155 shares of BTAI stock, worth $17,860. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,155Holding current value
$17,860% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding BTAI
# of Institutions
74Shares Held
7.2MCall Options Held
101KPut Options Held
205K-
Armistice Capital, LLC New York, NY2.99MShares$2.12 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA970KShares$689,0050.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$312,8860.0% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$189,3700.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA204KShares$144,5660.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $19.9M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...